panitumumab
- Generic Name
- panitumumab
- Brand Names
- Vectibix
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 339177-26-3
- Unique Ingredient Identifier
- 6A901E312A
- Background
Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent.
Panitumumab was granted FDA approval on 27 September 2006.
- Indication
美国FDA批准：用于野生型KRAS(外显子2)转移性结直肠癌(mCRC)患者的一线治疗。
- Associated Conditions
- Metastatic Colorectal Cancer (CRC)
- Associated Therapies
- -
Phase I/II Study of Panitumumab, Capecitabine and Oxaliplatin w EBRT for Esophageal Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-12-20
- Last Posted Date
- 2015-07-02
- Lead Sponsor
- Brian Czito
- Target Recruit Count
- 29
- Registration Number
- NCT00578071
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Effect of Panitumumab on the Pharmacokinetics of Irinotecan
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-11-26
- Last Posted Date
- 2016-04-12
- Lead Sponsor
- Amgen
- Target Recruit Count
- 28
- Registration Number
- NCT00563316
- Locations
- 🇨🇦
Research Site, Toronto, Ontario, Canada
Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-10-22
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 152
- Registration Number
- NCT00547157
Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck
- First Posted Date
- 2007-08-08
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 34
- Registration Number
- NCT00513383
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer
- First Posted Date
- 2007-07-30
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Amgen
- Target Recruit Count
- 154
- Registration Number
- NCT00508404
Study of Addition of Panitumumab to Chemoradiation Therapy in Patients With Locally Advanced Head and Neck Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-07-13
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 153
- Registration Number
- NCT00500760
PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-04-02
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 113
- Registration Number
- NCT00454779
- Locations
- 🇪🇸
Research Site, Madrid, Spain
PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)
- First Posted Date
- 2007-03-12
- Last Posted Date
- 2022-10-05
- Lead Sponsor
- Amgen
- Target Recruit Count
- 52
- Registration Number
- NCT00446446
SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial
- First Posted Date
- 2007-01-05
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 266
- Registration Number
- NCT00418938
PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1183
- Registration Number
- NCT00364013
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath